Meitheal Gets US Enoxaparin Approval

NKF-Controlled Meitheal Makes Progress With Lovenox Rival

Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.

Syringe
Meitheal Has Received FDA Approval For Enoxaparin • Source: Shutterstock

Injectables specialist Meitheal Pharmaceuticals has received US Food and Drug Administration approval for its generic version of Lovenox (enoxaparin).

Meitheal is licensing enoxaparin through its partnership with China’s Nanjing King-Friend Biochemical Pharmaceutical, which earlier this year paid $95m to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Products

The Politics Of Divisionals: How European Patentees Are Still Gaming The System

 
• By 

At Medicines for Europe’s legal affairs conference last month, divisional patents were once again a major subject of discussion. Attendees heard fresh details of how patentee games are preventing generics from hitting the market and restricting wider access to major medicines.

MSN Labs Swerves 2026 US Entresto Patent Ahead Of Separate July 15 Expiry

 
• By 

Novartis has filed an immediate appeal after a US district court ruled that MSN Labs would not infringe one of its key patents shielding its $7.8bn Entresto brand, and denied the originator injunctive relief.

UK Sitagliptin Prices Shoot Up In June

 
• By 

Multiple strengths of sitagliptin saw average price increases that topped our rundown of UK generic pricing data in June.

Biocon’s Denosumab Biosimilar Approved In The UK As Competition Grows In Europe

 

Denosumab biosimilar ranks are filling up in Europe as approvals flood in. Yet, little is known about the launch dates.

More from Generics Bulletin

Water Pressure: How European Industry Is Pushing Back On The UWWTD

 
• By 

Concern continues to build in the European generics industry over the threat posed by the EU’s Urban Wastewater Treatment Directive, which was one of the hottest topics of discussion at Medicines for Europe’s legal and annual conferences. And now, the association has intervened in a legal challenge.

Pertuzumab Leader Henlius Receives EU Accreditation For Production Lines

 
• By 

Shanghai Henlius Biotech has received EMA GMP certification for its HLX14 and HLX11 biosimilar production lines, paving the way for faster market entry in the EU and reinforcing its global manufacturing credentials.

Alvotech Boosts Packaging Abilities With Ivers-Lee Acquisition

 
• By 

Alvotech has acquired long-time partner Ivers-Lee to expand its in-house capacity for assembly and packaging ahead of key planned biosimilar launches in 2025, strengthening operational control and supporting global growth.